JP4721684B2 - Oral composition containing difructose anhydride - Google Patents
Oral composition containing difructose anhydride Download PDFInfo
- Publication number
- JP4721684B2 JP4721684B2 JP2004291541A JP2004291541A JP4721684B2 JP 4721684 B2 JP4721684 B2 JP 4721684B2 JP 2004291541 A JP2004291541 A JP 2004291541A JP 2004291541 A JP2004291541 A JP 2004291541A JP 4721684 B2 JP4721684 B2 JP 4721684B2
- Authority
- JP
- Japan
- Prior art keywords
- potassium
- dfa
- sodium
- excretion
- oral composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000008064 anhydrides Chemical class 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 15
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 25
- 239000011591 potassium Substances 0.000 claims description 25
- 229910052700 potassium Inorganic materials 0.000 claims description 25
- 230000029142 excretion Effects 0.000 claims description 23
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 22
- 239000011734 sodium Substances 0.000 claims description 22
- 229910052708 sodium Inorganic materials 0.000 claims description 22
- 230000001737 promoting effect Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 210000003608 fece Anatomy 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000015598 salt intake Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241001147838 Paenarthrobacter nicotinovorans Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 108010022991 levan fructotransferase Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Description
本発明は、ナトリウム及び／又はカリウム排泄促進機能をもつ経口組成物に関するものである。また、ナトリウム排泄促進機能をもつことにより、食塩過剰摂取に起因する疾患の予防及び改善作用をもつ経口組成物に関するものである。また、ナトリウム及び/又はカリウム排泄促進機能をもつことにより、腎臓病患者のナトリウム及び/又はカリウム摂取制限に対して役立つ事を目的とした経口組成物に関するものである。 The present invention relates to an oral composition having a function of promoting sodium and / or potassium excretion. In addition, the present invention relates to an oral composition having a function of preventing and ameliorating a disease caused by excessive intake of sodium chloride by having a function of promoting sodium excretion. The present invention also relates to an oral composition intended to be useful for limiting sodium and / or potassium intake in patients with kidney disease by having a function of promoting sodium and / or potassium excretion.
国民栄養調査によると、日本人の食塩摂取目安量である10gに対し、過剰に摂取している。食塩の過剰摂取は高血圧、ひいてはそれに伴う合併症の発生につながり、深刻な問題である。このような現状に対し、主に多糖類を主とした食事由来のナトリウムを体外に排泄する機能をもつ成分が特許文献１（WO99／33478，特開2002−87980号公報）に知られている。 According to the National Nutrition Survey, the Japanese intake of excessive salt is 10 g, which is the standard amount of salt intake in Japan. Excessive salt intake is a serious problem, leading to the development of hypertension and thus complications. In contrast to this situation, Patent Document 1 (WO99 / 33478, Japanese Patent Application Laid-Open No. 2002-87980) discloses a component having a function of excreting dietary sodium mainly from polysaccharides. .
また、カリウム排泄の調節は、腎臓の働きと、副腎皮質ホルモンの作用が密接に関連して行われるが、腎臓や副腎の機能のわるい人では、カリウムの排泄がうまくいかず、過剰にカリウムを摂取した場合・高カリウム血症(血漿中のカリウム濃度が上昇し、心臓症状がみられてくる)をおこす危険がある。腎臓病患者における食事コントロールの課題の一つとして、カリウムの摂取制限があり、調理の煩雑さや、食事の不味さが腎臓病者のQOL（Qualtiy of Life）を低下させている。このような現状に対し、様々な低カリウム食品や、クエン酸を主成分としてその他成分を含む事でカリウムイオンの吸収を抑制する事を目的とした食品（特許文献２：特開2000−270811号公報）が開発されている。 In addition, the regulation of potassium excretion is closely related to the action of the kidney and the action of adrenal cortex hormones. However, in people with poor kidney and adrenal function, potassium excretion does not go well and excessive potassium is used. Ingestion • Risk of hyperkalemia (increased plasma potassium level and heart symptoms). One of the challenges in diet control in patients with kidney disease is the restriction of potassium intake, and the complexity of cooking and the unpleasantness of the meals have lowered the quality of life (QOL) of those with kidney disease. In response to this situation, various low potassium foods and foods intended to suppress absorption of potassium ions by containing citric acid as the main component and other ingredients (Patent Document 2: JP 2000-270811 A) Gazette) has been developed.
本発明者等は、ダイフラクトース アンハイドライド（以下ＤＦＡと記す）について、その機能、応用について鋭意研究してきた。ＤＦＡの機能としてはビフィズス菌増殖作用を有すること（特許文献３：特公平３−５７８８号公報）やカルシウム吸収量を増やすこと（特許文献４：特開平１１−４３４３８号公報）、利尿作用をもつこと（特許文献５：特開２００３−３２１３７１号公報）が公知となっている。しかし、ＤＦＡがナトリウム及び／又はカリウムを腸管を経由して排泄促進させる機能をもつ事は知られていない。 The present inventors have diligently studied the function and application of difructose anhydride (hereinafter referred to as DFA). As a function of DFA, it has a bifidobacteria growth action (Patent Document 3: Japanese Patent Publication No. 3-5788), an increased amount of calcium absorption (Patent Document 4: Japanese Patent Laid-Open No. 11-43438), and has a diuretic action. (Patent Document 5: Japanese Patent Laid-Open No. 2003-321371) is publicly known. However, it is not known that DFA has a function of promoting excretion of sodium and / or potassium via the intestinal tract.
食塩の過剰摂取は生活習慣病に類される疾患、及びその合併症の発症、増悪の原因の一つとされており、食塩の過剰摂取の悪影響を改善する新たな組成物、予防改善剤、飲食品、飼料を提供することを目的とする。
また、ナトリウム及び／又はカリウムの排泄を促進させることにより、腎臓に障害を抱えている者の食事の自由度を向上することを目的とする。
Overdose of salt is one of the causes of life-style related diseases and their complications and exacerbations. New composition, preventive / improving agent, food and drink to improve adverse effects of overdose of salt The purpose is to provide goods and feed.
Moreover, it aims at improving the freedom degree of a meal of the person who has a disorder | damage | failure in a kidney by promoting the excretion of sodium and / or potassium.
本発明者らは、腸管を経由してナトリウム排泄を促進させる作用に注目し、研究を続けた結果、腸管を経由して体内ナトリウムの排泄を促進する機能をもち、さらに、食塩の過剰摂取に起因する疾患の予防、改善作用を有するＤＦＡの投与によって腸管を経由してナトリウム排泄が促進される事を見出した。さらに、本発明者らは、腸管を経由してカリウム排泄を促進させる作用に注目し、研究を続けた結果、腸管を経由してカリウム排泄を促進する機能をもつＤＦＡの投与によって腸管を経由して体内カリウムの排泄が促進される事を見出した。すなわち本発明はＤＦＡが腸管内のナトリウム及び／又はカリウムを排泄促進させる有効成分としての機能に着目した発明である。その機能を活かした本発明の主な構成は次のとおりである。
（１）ダイフラクトース アンハイドライド（ＤＦＡ）を含有することを特徴とするナトリウム及び／又はカリウム排泄促進用剤。
The present inventors paid attention to the action of promoting sodium excretion via the intestinal tract, and as a result of continuing research, the present inventors have a function of promoting excretion of sodium in the body via the intestinal tract. It has been found that sodium excretion is promoted via the intestinal tract by administration of DFA having an effect of preventing or improving the disease caused by the disease. Furthermore, the present inventors paid attention to the action of promoting potassium excretion via the intestinal tract, and as a result of continuing research, the administration of DFA having a function of promoting potassium excretion via the intestinal tract via the intestinal tract. And found that the excretion of potassium in the body is promoted. That is, the present invention focuses on the function of DFA as an active ingredient that promotes excretion of sodium and / or potassium in the intestinal tract. The main configuration of the present invention utilizing the function is as follows.
(1) A sodium and / or potassium excretion-promoting agent characterized by containing difructose anhydride (DFA).
本発明のＤＦＡを含有する経口組成物は腸管を経由して生体内ナトリウム排泄あるいは生体内カリウム排泄を促進する。
ナトリウム排泄を促進する事により、食塩の過剰摂取に起因する疾患の予防及び改善作用を示す。また、腎臓病患者のナトリウム及び／又はカリウム摂取制限に伴うQOLの低下を改善する。
飲食品、ペット動物用飼料としても提供できる。
The oral composition containing the DFA of the present invention promotes in vivo sodium excretion or in vivo potassium excretion via the intestinal tract.
It promotes sodium excretion, thereby preventing and ameliorating diseases caused by excessive salt intake. It also improves the QOL reduction associated with restriction of sodium and / or potassium intake in patients with kidney disease.
It can also be provided as food and drink and pet animal feed.
本発明でいうＤＦＡとは、２個のフラクトースが、互いに２点ずつで結合したアンヒドロ化環状二糖である。従来、カラメルなどに存在することが知られていたが、工業的には、イヌリンをイヌリン分解酵素、例えば、Arthrobacter sp.Ｈ６５−７株が産生するイヌリンフラクトトランスフェラーゼ（ＥＣ２.４.１.９３）により発酵させたり、レヴァンをArthrobacter nicotinovorans ＧＳ−９が産生するレヴァンフルクトトランスフェラーゼ（ＥＣ２.４.１.１０）により発酵させたりすることにより製造することができる。二分子のフラクトースの結合様式の差異により、誘導体が５種類存在し、それぞれ、ＤＦＡＩ、ＤＦＡII、ＤＦＡIII、ＤＦＡIV、ＤＦＡＶ と称される。本発明でいうＤＦＡとは、それら全てをいうが、本発明では、もっぱら、工業的生産の効率、精製してからの安定性などが優れているＤＦＡIII（di-D-fructofuranose-1,2’ : 2,3’ dianhydride）、ＤＦＡIV（di-D-fructofuranose-2,6’ : 6,2’ dianhydride）が好ましく使用される。
本発明に係る経口組成物は、ＤＦＡ を有効成分として含有するものであって、医薬品タイプ、飲食品タイプ、ペット動物用飼餌料タイプの組成物として利用することができ、例えば、ヒト又はペット動物用の医薬品、飲食品、調製粉乳、経腸栄養剤、健康飲食品、ペット飼餌料添加物など、最終的に経口投与可能な形態であれば制限はない。また、有効成分の含有量は、特に限定されない。
The DFA as used in the present invention is an anhydrohydrocyclic disaccharide in which two fructose are bonded to each other at two points. Conventionally, it was known to exist in caramel and the like, but industrially, inulin is produced by an inulin-degrading enzyme, for example, inulin fructotransferase (EC 2.4.1.93) produced by Arthrobacter sp. H65-7 strain. Or levan can be fermented with levanfructotransferase (EC 2.4.1.10) produced by Arthrobacter nicotinovorans GS-9. There are five types of derivatives due to the difference in the binding mode of bimolecular fructose, which are referred to as DFAI, DFAII, DFAIII, DFAIV, and DFAV, respectively. The DFA as used in the present invention refers to all of them, but in the present invention, DFAIII (di-D-fructofuranose-1,2 ′) which is excellent in industrial production efficiency, stability after purification, etc. : 2,3 'dianhydride) and DFAIV (di-D-fructofuranose-2,6': 6,2 'dianhydride) are preferably used.
The oral composition according to the present invention contains DFA as an active ingredient, and can be used as a pharmaceutical type, a food and drink type, a pet animal feed type composition, for example, a human or a pet animal. Pharmaceuticals, foods and drinks, prepared milk powder, enteral nutrients, health foods and drinks, pet food additives, etc., are not limited as long as they are finally orally administrable. Moreover, the content of the active ingredient is not particularly limited.
飲食品タイプの組成物として使用する場合には、ＤＦＡ又はその処理物をそのまま使用したり、他の食品ないし食品成分と併用したりして、適宜常法に従い使用できる。また、加工にあたっては、熱安定性、酸安定性が高いため、通常の食品加工方法がなんら問題なく適用できる。ＤＦＡを含有する食品タイプの経口組成物は、粉末、顆粒状、ペースト状、液状、懸濁状など特段の限定は受けない。例えば甘味料、酸味料、ビタミン剤その他ドリンク剤製造に常用される各種成分を用いて、健康ドリンクに製剤化することも例示できる。
予防や改善用としても摂取することができる。
When used as a food-and-drink type composition, DFA or a processed product thereof can be used as it is or in combination with other foods or food ingredients, and can be used according to conventional methods. Moreover, since the heat stability and acid stability are high in processing, a normal food processing method can be applied without any problem. The food type oral composition containing DFA is not subject to any particular limitation such as powder, granule, paste, liquid or suspension. For example, it can also be exemplified by formulating into a health drink using various ingredients commonly used in the production of sweeteners, sour agents, vitamins and other drinks.
It can be taken for prevention or improvement.
医薬品タイプの組成物として使用する場合、本有効成分は、種々の形態で投与される。その投与形態としては、例えば、錠剤、カプセル剤、顆粒剤、散剤、シロップ剤等による経口投与が例示できる。これらの各種製剤は、常法に従って主薬に賦形剤、結合剤、崩壊剤、滑沢剤、矯味矯臭剤、溶解補助剤、懸濁剤、コーティング剤などの医薬の製剤技術分野において通常使用しうる既知の補助剤を用いて製剤化することができる。その使用量は症状、年令、体重、剤形によって異なるが、通常は、成人に対して、経口投与の場合に１日当たり、体重１kg当たり０．５〜２０００ｍｇ、好ましくは１〜１０００ｍｇの範囲で投与するのがよい。
予防や改善用としても摂取することができる。
When used as a pharmaceutical type composition, the active ingredient is administered in various forms. Examples of the dosage form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations are usually used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspension agents, coating agents, etc. Can be formulated using known adjuvants. The amount used varies depending on symptoms, age, body weight, and dosage form, but is usually in the range of 0.5 to 2000 mg, preferably 1 to 1000 mg per kg of body weight per day for oral administration to adults. It is better to administer.
It can be taken for prevention or improvement.
ペット動物も富栄養化あるいは人と同様の食物をとる機会が増えるので、ペット動物用剤あるいはペット飼料に添加してナトリウム及び／又はカリウム排出を促進することが有用である。また、予防や改善用としても摂取することができる。 Because pet animals also have an increased chance of eutrophication or eating foods similar to humans, it is useful to add sodium and / or potassium excretion by adding them to pet animal preparations or pet feed. It can also be taken for prevention or improvement.
〔実施例〕
以下の実施例をもって本発明をより詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。
〔Example〕
The present invention will be described in more detail with reference to the following examples, which are merely illustrative and the present invention is not limited thereto.
ＤＦＡの腸管経由ナトリウム排泄促進機能を調べた。
Wistar系雄ラット（3週齢）24匹を3日間固形飼料で予備飼育した後、基本食７g（ナトリウム14mg含有）を３日間与え、３群に分けた。それぞれに基本食７ｇのみ、基本食にＤＦＡIII１．０g又はショ糖 １．０gずつ足した飼料を与えた。３週間の本飼育中、最後の7日間の糞を採取し、凍結乾燥処理を行ったのち、乾燥糞中のナトリウム濃度を原子吸光測定し、調べた。
結果を図1に示す。
この結果から明らかなように、ＤＦＡの摂取により、糞便中ナトリウム濃度の上昇が認められた。また、各群の乾燥糞重量は基本食群（4.3±0.1g）、ショ糖群（4.3±0.2g）、ＤＦＡIII群（4.8±0.1g）であった。
The ability of DFA to promote sodium excretion via the intestinal tract was examined.
After 24 Wistar male rats (3 weeks old) were preliminarily raised on a solid feed for 3 days, 7 g of basic food (containing 14 mg of sodium) was given for 3 days and divided into 3 groups. Only 7 g of basic food was given to each, and feed obtained by adding 1.0 g of DFA III or 1.0 g of sucrose to the basic food was given. During the last three weeks of the breeding, feces were collected for the last 7 days and subjected to lyophilization treatment, and then the sodium concentration in the dried feces was measured by atomic absorption measurement.
The results are shown in Figure 1.
As is clear from this result, an increase in fecal sodium concentration was observed with the intake of DFA. Moreover, the dry feces weight of each group was a basic food group (4.3 ± 0.1 g), a sucrose group (4.3 ± 0.2 g), and a DFA III group (4.8 ± 0.1 g).
ＤＦＡの腸管経由カリウム排泄促進機能を調べた。
Wistar系雄ラット（3週齢）24匹を3日間固形飼料で予備飼育した後、基本食７g（カリウム50.4mg含有）を３日間与え、３群に分けた。それぞれに基本食７ｇのみ、基本食にＤＦＡIII１．０g、ショ糖 １．０gずつ足した飼料を与えた。３週間の本飼育中、最後の7日間の糞を採取し、凍結乾燥処理を行ったのち、乾燥糞中のカリウム濃度を原子吸光測定し、調べた。
結果を図２に示す。
この結果から明らかなように、ＤＦＡの摂取により、糞便中カリウム濃度の上昇が認められた。また、各群の乾燥糞重量は基本食群（4.3±0.1g）、ショ糖群（4.3±0.2g）、ＤＦＡIII群（4.8±0.1g）であった。
The ability of DFA to promote potassium excretion via the intestinal tract was examined.
After 24 Wistar male rats (3 weeks old) were preliminarily raised on a solid feed for 3 days, 7 g of basic food (containing 50.4 mg of potassium) was given for 3 days and divided into 3 groups. Only 7 g of basic food was given to each, and a feed obtained by adding 1.0 g of DFA III and 1.0 g of sucrose to the basic food was given. During the last three weeks of breeding, feces from the last 7 days were collected and lyophilized, and the potassium concentration in the dried feces was measured by atomic absorption measurement.
The results are shown in FIG.
As is clear from this result, an increase in fecal potassium concentration was observed with the intake of DFA. Moreover, the dry feces weight of each group was a basic food group (4.3 ± 0.1 g), a sucrose group (4.3 ± 0.2 g), and a DFA III group (4.8 ± 0.1 g).
ＤＦＡIIIを含有する錠剤の処方例を示す。
処方例１ 錠剤 （配合量：質量％）
ＤＦＡIII ７７
コーンスターチ ２０
グアーガム １
ステアリン酸マグネシウム １
The formulation example of the tablet containing DFAIII is shown.
Formulation Example 1 Tablet (Amount: Mass%)
DFAIII 77
Cornstarch 20
Guar gum 1
Magnesium stearate 1
ＤＦＡIIIを含有するジュースの処方例を示す。
処方例２ ジュース （配合量：質量％）
ＤＦＡIII １０
冷凍濃縮温州ミカン果汁 ５
クエン酸 ０．２
Ｌ−アスコルビン酸 ０．０２
香料 ０．２
色素 ０．１
水 ８４．４８
The formulation example of the juice containing DFAIII is shown.
Formulation Example 2 Juice (Amount:% by mass)
DFAIII 10
Frozen and concentrated Wenzhou mandarin orange juice 5
Citric acid 0.2
L-ascorbic acid 0.02
Fragrance 0.2
Dye 0.1
Water 84.48
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004291541A JP4721684B2 (en) | 2004-10-04 | 2004-10-04 | Oral composition containing difructose anhydride |
| PCT/JP2005/018346 WO2006038613A1 (en) | 2004-10-04 | 2005-10-04 | Oral composition containing difructose anhydride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004291541A JP4721684B2 (en) | 2004-10-04 | 2004-10-04 | Oral composition containing difructose anhydride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006104103A JP2006104103A (en) | 2006-04-20 |
| JP4721684B2 true JP4721684B2 (en) | 2011-07-13 |
Family
ID=36142686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004291541A Active JP4721684B2 (en) | 2004-10-04 | 2004-10-04 | Oral composition containing difructose anhydride |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4721684B2 (en) |
| WO (1) | WO2006038613A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5285852B2 (en) * | 2006-12-28 | 2013-09-11 | 株式会社ファンケル | DFAIII production method and DFAIII-rich plant extract |
| JP4880508B2 (en) * | 2007-03-23 | 2012-02-22 | 日本甜菜製糖株式会社 | Immunoglobulin absorption promoting composition |
| JP7137368B2 (en) * | 2017-09-21 | 2022-09-14 | 株式会社ファンケル | Composition for promoting sodium excretion and/or suppressing sodium absorption |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143438A (en) * | 1997-07-29 | 1999-02-16 | Nippon Beet Sugar Mfg Co Ltd | Calcium absorption-enhancing composition |
| JP2000204042A (en) * | 1999-01-13 | 2000-07-25 | Nippon Mitsubishi Oil Corp | Cyclic oligosaccharide |
| JP2003321371A (en) * | 2002-04-26 | 2003-11-11 | Fancl Corp | Diuretic |
-
2004
- 2004-10-04 JP JP2004291541A patent/JP4721684B2/en active Active
-
2005
- 2005-10-04 WO PCT/JP2005/018346 patent/WO2006038613A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143438A (en) * | 1997-07-29 | 1999-02-16 | Nippon Beet Sugar Mfg Co Ltd | Calcium absorption-enhancing composition |
| JP2000204042A (en) * | 1999-01-13 | 2000-07-25 | Nippon Mitsubishi Oil Corp | Cyclic oligosaccharide |
| JP2003321371A (en) * | 2002-04-26 | 2003-11-11 | Fancl Corp | Diuretic |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006038613A1 (en) | 2006-04-13 |
| JP2006104103A (en) | 2006-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2779963B2 (en) | Bifidobacterium growth promoter | |
| JP3514955B2 (en) | Calcium absorption enhancing composition | |
| JP2010120945A (en) | Inulin product with improved nutritional property | |
| JP2005068060A (en) | Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin | |
| KR101356330B1 (en) | Hepatic function remedial agent | |
| WO2006054429A1 (en) | Oral composition containing difructose anhydride | |
| JP3749978B2 (en) | Bone formation enhancing composition exhibiting anti-osteoporosis effect | |
| JP2010111646A (en) | Treating agent for ulcerative colitis | |
| JP4721684B2 (en) | Oral composition containing difructose anhydride | |
| JPH1084909A (en) | Intestinal butyric acid concentration increase accelerating agent | |
| JP2009107987A (en) | Muscle enhancer | |
| JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
| JP4601091B2 (en) | Cyclic oligosaccharide | |
| JPWO2010104175A1 (en) | Oral composition | |
| JP2009526748A (en) | Calcium absorption promoter | |
| JP4127863B2 (en) | Intestinal environment improving composition | |
| JP2009120502A (en) | Chitosan-containing composition | |
| WO2007001006A1 (en) | Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same | |
| JP2007022982A (en) | Ameliorating agent for bowel movement and food for ameliorating bowel movement | |
| JP2005350371A (en) | Nutrient composition for hepatopathic patient | |
| JP2002255832A (en) | Mineral absorption-promoting agent and anemia- improving agent | |
| JP3343487B2 (en) | Emotional disorder improver | |
| CN106573034B (en) | Marine peptides and fish nucleotides, compositions and uses thereof for lowering blood glucose | |
| JP2004161619A (en) | Osteogenic promoting composition | |
| JP2007291011A (en) | Preventive or therapeutic agent of inflammatory intestinal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070726 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110329 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110405 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4721684 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |